Arsanis Biosciences GmbH, an early stage biotechnology company developing anti-infective human monoclonal antibodies, today announced the award of a grant for the development of monoclonal antibody therapeutics against nosocomial infections from the Austrian Research Promotion Agency , the leading public funding agency for translational research in Austria.
